Brokerages Anticipate CRISPR Therapeutics AG (NASDAQ:CRSP) Will Post Quarterly Sales of $4.23 Million

Equities research analysts forecast that CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) will post $4.23 million in sales for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for CRISPR Therapeutics’ earnings, with estimates ranging from $200,000.00 to $14.80 million. CRISPR Therapeutics reported sales of $900.70 million during the same quarter last year, which indicates a negative year-over-year growth rate of 99.5%. The business is scheduled to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that CRISPR Therapeutics will report full year sales of $187.03 million for the current year, with estimates ranging from $1.00 million to $940.00 million. For the next year, analysts forecast that the company will post sales of $231.76 million, with estimates ranging from $3.37 million to $727.30 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover CRISPR Therapeutics.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last posted its quarterly earnings results on Monday, May 9th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($1.94) by ($0.38). The business had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $2.45 million. CRISPR Therapeutics had a net margin of 34.04% and a return on equity of 12.77%. The firm’s quarterly revenue was up 74.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.51) EPS.

A number of analysts have recently issued reports on CRSP shares. Brookline Capital Management reiterated a “buy” rating and set a $143.00 target price on shares of CRISPR Therapeutics in a report on Monday, February 14th. Brookline Capital Acquisition started coverage on CRISPR Therapeutics in a report on Monday, February 14th. They set a “buy” rating and a $143.00 target price for the company. The Goldman Sachs Group decreased their target price on CRISPR Therapeutics from $52.00 to $46.00 and set a “neutral” rating for the company in a report on Tuesday. Stifel Nicolaus decreased their target price on CRISPR Therapeutics to $64.00 in a report on Wednesday, February 16th. They noted that the move was a valuation call. Finally, Barclays decreased their target price on CRISPR Therapeutics from $107.00 to $99.00 in a report on Tuesday, May 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics currently has an average rating of “Buy” and a consensus price target of $118.63.

Institutional investors and hedge funds have recently modified their holdings of the stock. Capital Impact Advisors LLC bought a new position in CRISPR Therapeutics during the 4th quarter worth $26,000. Elkhorn Partners Limited Partnership grew its stake in shares of CRISPR Therapeutics by 180.0% in the fourth quarter. Elkhorn Partners Limited Partnership now owns 350 shares of the company’s stock worth $27,000 after purchasing an additional 225 shares in the last quarter. Kistler Tiffany Companies LLC grew its stake in shares of CRISPR Therapeutics by 6,250.0% in the fourth quarter. Kistler Tiffany Companies LLC now owns 381 shares of the company’s stock worth $29,000 after purchasing an additional 375 shares in the last quarter. CI Investments Inc. bought a new position in shares of CRISPR Therapeutics in the third quarter worth $30,000. Finally, IronBridge Private Wealth LLC bought a new position in shares of CRISPR Therapeutics in the fourth quarter worth $30,000. Hedge funds and other institutional investors own 56.12% of the company’s stock.

CRSP traded up $0.79 during midday trading on Friday, hitting $53.17. The company’s stock had a trading volume of 55,104 shares, compared to its average volume of 1,525,994. The firm has a market cap of $4.12 billion, a P/E ratio of 14.51 and a beta of 2.05. The firm has a 50-day moving average price of $58.32 and a two-hundred day moving average price of $65.95. CRISPR Therapeutics has a 52-week low of $42.51 and a 52-week high of $169.76.

CRISPR Therapeutics Company Profile (Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Stories

Get a free copy of the Zacks research report on CRISPR Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.